Výsledky vyhledávání

Phase 2 study of ipilimumab, nivolumab, and tocilizumab combined with stereotactic body radiotherapy in patients with refractory pancreatic cancer (TRIPLE-R)

Autor: Inna M. Chen, Marco Donia, Christopher A. Chamberlain, Agnete W.P. Jensen, Arianna Draghi, Susann Theile, Kasper Madsen, Jane P. Hasselby, Anders Toxværd, Estrid Høgdall, Torben Lorentzen, Eva E. Wilken, Poul Geertsen, Inge M. Svane, Julia S. Johansen, Dorte Nielsen

Publikováno v: European journal of cancer (Oxford, England : 1990). 180

Interleukin-6 blockade and radiation combined with immunotherapy may modulate the tumour microenvironment to overcome immune resistance. We assessed the efficacy of ipilimumab, nivolumab, and tocilizumab combined with stereotactic body radiotherapy (

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e731b675c5c0616c5b4cc9be6bec205
https://pubmed.ncbi.nlm.nih.gov/36592507

Zobrazit plný text záznamu

Randomized Phase II Study of Nivolumab with or Without Ipilimumab Combined with Stereotactic Body Radiotherapy for Refractory Metastatic Pancreatic Cancer (CheckPAC)

Autor: Inna M. Chen, Julia S. Johansen, Susann Theile, Jessica X. Hjaltelin, Sif I. Novitski, Søren Brunak, Jane P. Hasselby, Gro L. Willemoe, Torben Lorentzen, Kasper Madsen, Benny V. Jensen, Eva E. Wilken, Poul Geertsen, Claus Behrens, Christian Nolsoe, Kirstine L. Hermann, Inge Marie Svane, Dorte Nielsen

Publikováno v: Chen, I M, Johansen, J S, Theile, S, Hjaltelin, J X, Novitski, S I, Brunak, S, Hasselby, J P, Willemoe, G L, Lorentzen, T, Madsen, K, Jensen, B V, Wilken, E E, Geertsen, P, Behrens, C, Nolsoe, C, Hermann, K L, Svane, I M & Nielsen, D 2022, ' Randomized Phase II Study of Nivolumab with or Without Ipilimumab Combined with Stereotactic Body Radiotherapy for Refractory Metastatic Pancreatic Cancer (CheckPAC) ', Journal of Clinical Oncology, vol. 40, no. 27, pp. 3180-3189 . https://doi.org/10.1200/JCO.21.02511

PURPOSE To evaluate the clinical benefit of nivolumab with or without ipilimumab in combination with stereotactic body radiotherapy (SBRT) in patients with refractory metastatic pancreatic cancer (mPC). METHODS Between November 2016 and December 2019

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d517399ede567a550cd80bf191cfef2
https://curis.ku.dk/portal/da/publications/randomized-phase-ii-study-of-nivolumab-with-or-without-ipilimumab-combined-with-stereotactic-body-radiotherapy-for-refractory-metastatic-pancreatic-cancer-checkpac(ddc8b5b7-4bb4-4716-9c2f-485d7189a5c7).html

Zobrazit plný text záznamu

Randomized phase 2 study of nivolumab with or without ipilimumab combined with stereotactic body radiotherapy in pretreated patients with metastatic biliary tract cancer

Autor: Alice Markussen, Julia S. Johansen, Finn Ole Larsen, Susann Theile, Jane P. Hasselby, Gro Linno Willemoe, Torben Lorentzen, Kasper Madsen, Eva E. Wilken, Poul F. Geertsen, Claus Behrens, Inge Marie Svane, Dorte Nielsen, Inna Markovna Chen

Publikováno v: Journal of Clinical Oncology. 41:545-545

545 Background: The treatment options for patients with biliary tract cancer (BTC) are limited. The aim of this study was to evaluate the clinical benefit of nivolumab with or without ipilimumab combined with stereotactic body radiotherapy (SBRT) in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8059abd94afbed1dbf96b4373507950e
https://doi.org/10.1200/jco.2023.41.4_suppl.545

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Prospective evaluation of acute toxicity and patient reported outcomes in anal cancer and plan optimization

Autor: Eva Serup-Hansen, Jørgen B. B. Petersen, Jolanta Hansen, Karen-Lise Garm Spindler, Camilla Kronborg, Eva E. Wilken, Lars Nyvang, Annette Schouboe, A.C. Lefèvre

Publikováno v: Kronborg, C, Serup-Hansen, E, Lefevre, A, Wilken, E E, Petersen, J B, Hansen, J, Schouboe, A, Nyvang, L & Spindler, K-L G 2018, ' Prospective evaluation of acute toxicity and patient reported outcomes in anal cancer and plan optimization ', Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, vol. 128, no. 2, pp. 375-379 . https://doi.org/10.1016/j.radonc.2018.06.006

BACKGROUND AND PURPOSE: Chemoradiotherapy (CRT) is the standard therapy for localized anal cancer (AC), but this treatment is associated with substantial toxicity. However, there is a lack of prospectively collected toxicity and patient reported outc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af9a3a71a0d0f636b07829db74d7a5af
https://doi.org/10.1016/j.radonc.2018.06.006

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Vyhledávací nástroje:

Upřesnit hledání